MSMuloongo Simuzingili

Muloongo Simuzingili

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Muloongo Simuzingili has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Single age cohort health risk distribution of pneumococcal disease among US adults in 2022

    by Muloongo Simuzingili, Yi Zheng, Lei Ai, Amy Huang, Kwame Owusu-Edusei

    Background: Pneumococcal Disease (PD) is associated with significant health and economic burden in the US. The Advisory Committee on Immunization Practices (ACIP) recommends pneumococcal vaccination for adults with immunocompromised conditions and chronic medical conditions who are at increased risk of PD. This study examines the distribution of PD risk conditions among US adults by single age cohorts, based on the ACIP classification of conditions. Methods: A retrospective observational study was conducted among individuals enrolled in US IBM@ MarketScan Commercial Claims and Encounters (CCAE) in 2022. The risk of PD (low-risk (LR), moderate-risk (MR), and high-risk (HR) of PD) among adults aged ≥ 18 years was classified using International Classification of Diseases, Clinical Modification version 10 (ICD-10-CM) and Current Procedural Terminology version 4 codes, based on a 5-year lookback period among individuals with continuous enrollment. Risk distributions were summarized by single-year age cohort, and the clinical conditions comprising the MR and HR categories were described. Supplementary analyses summarized risk distributions using broader age categories, and sensitivity analyses assessed the impact of using a shorter 2-year lookback period and removing the continuous enrollment requirement. Results: The study population included more females (52.2%) than males (47.8%) and was more likely to be aged 18–49 years (55.5%) and living in the South region (44.9%). Most adults were classified as LR (58.4%), followed by MR (28.1%) and HR (13.5%). While the LR and MR groups were predominantly aged 18–49 years, the HR group was primarily aged 50–64 years and female. Chronic lung disease and chronic heart disease were the most prevalent MR conditions, and cancer was the most prevalent HR condition. Sensitivity analyses showed similar age-related patterns, although the primary analysis classified higher proportions of adults as MR or HR than analyses using a 2-year lookback period or the full sample without the continuous enrollment requirement. Conclusions: This study addresses an evidence gap by providing descriptive single-age cohort estimates of pneumococcal disease risk distribution among commercially insured US adults. These estimates may support future modelling analyses, contextualize age-specific risk patterns, and inform hypothesis generation regarding pneumococcal disease risk across adult age groups. Clinical trial: Not applicable.

  • Open Access

    Cost-effectiveness analysis of pneumococcal conjugate vaccines, PCV21 vs PCV20, in adults aged ≥60 years in Germany

    by Muloongo Simuzingili, Peter P. Mueller, Lisa M. Oexle, Marion de Lepper, Zinan Yi, Kwame Owusu-Edusei

    1. S. pneumoniae is a gram-positive bacterium with over 100 distinct serotypes, defined by differences in polysaccharide capsule proteins [1].Approximately one-third of pneumococcal serotypes cause...

  • Open Access

    The Health and Economic Impact of the Adult-specific 21-valent (aPCV21) Pneumococcal Conjugate Vaccine vs PCV20 on Invasive Pneumococcal Disease Among Adults Aged 65 years in the United Kingdom: A Modeling Study

    by Peter P. Mueller, Muloongo Simuzingili, Ian R. Matthews, Zinan Yi, Kwame Owusu-Edusei

    Introduction: This study compared the health and economic impact of the 21-valent pneumococcal conjugate vaccine (aPCV21) vs the 20-valent pneumococcal conjugate vaccine (PCV20) on invasive pneumococcal disease (IPD) and post-meningitis sequelae (PMS) among adults aged 65 years and older in the United Kingdom (UK). Methods: A published Markov model was used to simulate a single-cohort of vaccine-naïve adults who became eligible for age-based vaccination at age 65 years, with uptake occurring over time. The cohort was followed until a maximum age of 100 years. Model inputs were derived from publicly available national health data and published reports. Outcomes were discounted at 3.5% annually, and costs were adjusted to the 2024 Great Britain Pound (£). Additional analyses explored the impact of changing the age-based recommendation from 65 years to 75 years. Scenarios involving instantaneous vaccine uptake rates were included as part of the sensitivity analyses. A deterministic sensitivity analysis was performed on the incremental direct medical costs between vaccinating with aPCV21 vs PCV20 under the age-based recommendation of 65 years. Results: Using an age-based recommendation of 65 years, aPCV21 led to fewer cases, deaths, and costs than PCV20. Compared with PCV20, aPCV21 averted an additional 138 IPD cases, 1 PMS case, and 22 IPD deaths, saving £1.2 million in direct medical costs. Raising the age-based recommendation from 65 to 75 years and using aPCV21 (or PCV20, respectively), resulted in 120 (92) additional IPD cases, 2 (1) additional PMS case(s), 19 (14) additional IPD death(s), and an extra £1.1 (£0.8) million in direct medical costs. The deterministic sensitivity analysis showed that aPCV21 reduced direct medical costs across all parameter ranges. Conclusions: Compared with PCV20, aPCV21 prevented more IPD cases, IPD deaths, and direct medical costs among older adults in the UK. Changing the age-based recommendation from age 65 to 75 resulted in worse health and economic outcomes.

  • Open Access

    Cost-effectiveness analysis of pneumococcal vaccination of at-risk and high-risk adults aged 18–64 years in Switzerland using PCV21

    by Muloongo Simuzingili, Zinan Yi, Andrea Favre-Bulle, Thomas Mutschler, Eleana Tsoumani, Kwame Owusu-Edusei

    Pneumococcal disease (PD) collectively describes Streptococcus pneumoniae infections at various anatomical sites1,2. Infections of usually sterile sites are classified as invasive pneumococcal dise...

  • Open Access

    The health and economic burden of invasive pneumococcal diseases attributable to PCV21 versus PCV20 serotypes among adults aged ≥ 45 years in Spain

    by Muloongo Simuzingili, Silvia Fernández-Soberón, Zinan Yi, Nicole Cossrow, Kelly D. Johnson, Kwame Owusu-Edusei

    Background: The 21-valent pneumococcal conjugate vaccine (PCV21) is a new vaccine that includes eight serotypes not found in any currently licensed vaccines. This study estimates the lifetime clinical and economic burden of invasive pneumococcal disease (IPD) in Spain attributable to PCV21 serotypes compared to PCV20 serotypes among Spanish adults aged ≥ 45 years. Methods: Using a published state-transition Markov model, the lifetime IPD cases, deaths, and direct medical costs (in 2024 euros) associated with serotypes included in PCV21 and PCV20 were estimated among adults aged 45–64 and ≥ 65 years across three risk groups (low-risk, at-risk, and high-risk). A one-way sensitivity analysis was performed to identify key model inputs influencing the incremental costs of IPD. Results: PCV21 serotypes were associated with approximately 17–20% more lifetime IPD cases and deaths than PCV20 serotypes among adults aged ≥ 45 years. The estimated lifetime direct medical cost for PCV21 serotypes (€291 million) was 14% higher than that of PCV20 (€255 million) among adults aged 45–64 years. Similarly, PCV21 serotypes (€193 million) were 20% higher than PCV20 serotypes (€161 million) among those aged ≥ 65 years. The eight unique serotypes targeted by PCV21 accounted for 29,501 cases and 6,059 deaths (approximately 18–19% of PCV21 serotypes), contributing over €97 million to direct lifetime IPD costs. The highest burden was consistently observed in high-risk groups. Conclusions: The serotypes targeted by PCV21 impose a significantly higher health and economic burden of IPD in Spain relative to PCV20. Consequently, PCV21 may help reduce the health and economic burden of IPD among Spanish adults, supporting its incorporation into national vaccination guidelines and adult immunization strategies.


  • Ratio of Infections to COVID-19 Cases and Hospitalizations in the United States based on SARS-CoV-2 Seroprevalence Data, September 2021–February 2022

    by Yangyang Deng, Yun Kim, Anna Bratcher, Jefferson M Jones, Muloongo Simuzingili, Adi V Gundlapalli, Melissa Briggs Hagen, Ronaldo Iachan, Kristie E N Clarke

    Background: Understanding the risk of hospitalization from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections can guide effective public health interventions and severity assessments. This study calculated infection–hospitalization ratios (IHRs) and infection–case ratios (ICRs) to understand the relationship between SARS-CoV-2 infections, cases, and hospitalizations among different age groups during periods of Delta and Omicron variant predominance. Methods: After calculating antinucleocapsid SARS-CoV-2 antibody seroprevalence using residual commercial laboratory serum specimens, 2 ratios were computed: (1) IHRs using coronavirus disease 2019 hospitalization data and (2) ICRs using Centers for Disease Control and Prevention surveillance data. Ratios were calculated across age groups (0–17, 18–49, 50–69, and ≥70 years) for 2 time periods (September–December 2021 [Delta] and December 2021–February 2022 [Omicron]). Results: Pediatric IHRs increased from 76.7 during Delta to 258.4 during Omicron. Adult IHRs ranged from 3.0 (≥70 years) to 21.6 (18–49 years) during Delta and from 10.0 (≥70 years) to 119.1 (18–49 years) during Omicron. The pediatric ICR was lower during the Delta period (2.7) compared with the Omicron period (3.7). Adult ICRs (Delta: 1.1 [18–49 years] to 2.1 [70+ years]; Omicron: 2.2 [>70+ years] to 2.9 [50–69 years]) were lower than pediatric ICRs during both time periods. Conclusions: All age groups exhibited a lower proportion of infections associated with hospitalization in the Omicron period than the Delta period; the proportion of infections associated with hospitalization increased with each older age group. A lower proportion of SARS-CoV-2 infections were associated with reported cases in the Omicron period than in the Delta period among all age groups.